LAM
ALNY icon

L2 Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

L2 Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231K Buy
768
+20
+3% +$6.03K 0.02% 380
2026
Q1 		$247K Buy
748
+77
+11% +$26.2K 0.02% 349
2025
Q4 		$267K Buy
671
+60
+10% +$26.6K 0.04% 312
2025
Q3 		$279K Buy
+611
New +$249K 0.04% 300

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

L2 Asset Management's ALNY Position: Q2 2026 in Review

L2 Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 2.7% in Q2 2026, buying an estimated $6.03K and bringing the position to 768 shares worth $231K. The position accounts for 0.02% of the portfolio, ranked #380.

L2 Asset Management first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $279K in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • L2 Asset Management held 768 shares of Alnylam Pharmaceuticals worth $231K as of Q2 2026.
  • L2 Asset Management bought 20 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $6.03K.
  • Alnylam Pharmaceuticals made up 0.02% of L2 Asset Management's portfolio in Q2 2026, its #380 holding.
  • L2 Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • L2 Asset Management's Alnylam Pharmaceuticals position peaked at $279K in Q3 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on L2 Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.